항체치료제
-
EU101
Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of cancer.
Discovery
Non-clinical
Phase I
Phase II
-
EU103
Fully humanized therapeutic monoclonal antibody. This could convert type II macrophage to Type I. Anti-tumor efficacy of the antibody can be achieved by modulating tumor microenvironment.
Discovery
Non-clinical
Phase I
Phase II
-
EU501(HER2 x 4-1BB)
4-1BB mAb-based, tumor antigen targeting bispecific antibodies.
Discovery
Non-clinical
Phase I
Phase II